$489.02
-0.22[-0.04%]
At close: Apr 25
$489.02
0[0.00%]
PreMarket: 5:19PM EDT
IDEXX Laboratories
(NASDAQ:IDXX)IDEXX Laboratories Stock (NASDAQ:IDXX), Analyst Ratings, Price Targets, Predictions
IDEXX Laboratories Inc has a consensus price target of $533.75, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Barclays, and Piper Sandler on February 6, 2024, February 6, 2024, and January 30, 2024. With an average price target of $603.33 between JP Morgan, Barclays, and Piper Sandler, there's an implied 23.38% upside for IDEXX Laboratories Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Barclays
Piper Sandler
Goldman Sachs
Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for IDEXX Laboratories
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/06/2024 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 28.83% | JP Morgan | Chris Schott | $600 → $630 | Maintains | Overweight | Get Alert |
| 02/06/2024 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 33.94% | Barclays | Balaji Prasad | $605 → $655 | Maintains | Overweight | Get Alert |
| 01/30/2024 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 7.36% | Piper Sandler | David Westenberg | → $525 | Downgrade | Overweight → Neutral | Get Alert |
| 01/17/2024 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 32.92% | Goldman Sachs | Nathan Rich | $500 → $650 | Maintains | Buy | Get Alert |
| 11/06/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 7.36% | Piper Sandler | David Westenberg | $520 → $525 | Maintains | Overweight | Get Alert |
| 11/03/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 2.25% | Goldman Sachs | Nathan Rich | $578 → $500 | Maintains | Buy | Get Alert |
| 11/02/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 12.47% | JP Morgan | Chris Schott | $600 → $550 | Maintains | Overweight | Get Alert |
| 11/02/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 21.06% | Barclays | Balaji Prasad | $590 → $592 | Maintains | Overweight | Get Alert |
| 10/30/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | -5.93% | Stifel | Jonathan Block | $500 → $460 | Maintains | Hold | Get Alert |
| 09/15/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 2.25% | Stifel | Jonathan Block | $525 → $500 | Maintains | Hold | Get Alert |
| 08/03/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 22.69% | Morgan Stanley | Erin Wright | $590 → $600 | Maintains | Overweight | Get Alert |
| 08/02/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 22.69% | JP Morgan | Chris Schott | $550 → $600 | Maintains | Overweight | Get Alert |
| 08/02/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 22.69% | Atlantic Equities | Steve Chesney | → $600 | Downgrade | Overweight → Neutral | Get Alert |
| 06/07/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 22.69% | Atlantic Equities | Steve Chesney | → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 22.69% | Atlantic Equities | Steve Chesney | → $600 | Reiterates | → Overweight | Get Alert |
| 03/23/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 20.65% | Morgan Stanley | Erin Wright | $543 → $590 | Maintains | Overweight | Get Alert |
| 02/08/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 20.65% | Barclays | Balaji Prasad | $582 → $590 | Maintains | Overweight | Get Alert |
| 02/07/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 12.47% | JP Morgan | Chris Schott | $525 → $550 | Maintains | Overweight | Get Alert |
| 02/07/2023 | IDXX | Buy Now | IDEXX Laboratories | $489.02 | 22.69% | Atlantic Equities | Steve Chesney | $470 → $600 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for IDEXX Laboratories (IDXX)?
The latest price target for IDEXX Laboratories (NASDAQ: IDXX) was reported by JP Morgan on February 6, 2024. The analyst firm set a price target for $630.00 expecting IDXX to rise to within 12 months (a possible 28.83% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IDEXX Laboratories (IDXX)?
The latest analyst rating for IDEXX Laboratories (NASDAQ: IDXX) was provided by JP Morgan, and IDEXX Laboratories maintained their overweight rating.
When was the last upgrade for IDEXX Laboratories (IDXX)?
The last upgrade for IDEXX Laboratories Inc happened on July 21, 2022 when Goldman Sachs raised their price target to $435. Goldman Sachs previously had a neutral for IDEXX Laboratories Inc.
When was the last downgrade for IDEXX Laboratories (IDXX)?
The last downgrade for IDEXX Laboratories Inc happened on January 30, 2024 when Piper Sandler changed their price target from N/A to $525 for IDEXX Laboratories Inc.
When is the next analyst rating going to be posted or updated for IDEXX Laboratories (IDXX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on February 6, 2024 so you should expect the next rating to be made available sometime around February 6, 2025.
Is the Analyst Rating IDEXX Laboratories (IDXX) correct?
While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a maintained with a price target of $600.00 to $630.00. The current price IDEXX Laboratories (IDXX) is trading at is $489.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.